EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017

  • ID: 4091102
  • Report
  • February 2017
  • 89 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Bayer AG
  • Laboratoire HRA Pharma
  • Ogeda SA
  • Repros Therapeutics Inc
  • MORE
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying your bladder, constipation and backache or leg pains.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 1, 4 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Bayer AG
  • Laboratoire HRA Pharma
  • Ogeda SA
  • Repros Therapeutics Inc
  • MORE
Introduction

Uterine Leiomyoma (Uterine Fibroids) - Overview

Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Bayer AG

BioSpecifics Technologies Corp

Dongkook Pharmaceutical Co Ltd

Kissei Pharmaceutical Co Ltd

Laboratoire HRA Pharma

Ogeda SA

Repros Therapeutics Inc

Takeda Pharmaceutical Company Ltd

Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles

collagenase clostridium histolyticum - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Endometriosis and Uterine Fibroids - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elagolix sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVE-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLH-2109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relugolix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telapristone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triptorelin biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulipristal acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vilaprisan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPE-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPEA-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects

Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products

Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones

Featured News & Press Releases

Jan 30, 2017: FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex in the Treatment of Uterine Fibroids

Jan 25, 2017: Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Jan 17, 2017: Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

Dec 12, 2016: Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex in the Treatment of Symptomatic Uterine Fibroids

Nov 21, 2016: FIBRISTAL, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment

Nov 14, 2016: Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex Delivered Orally and Vaginally for the Treatment of Uterine Fibroids

Oct 17, 2016: Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City

Oct 13, 2016: Latest clinical data on Bayer mid-stage candidate Vilaprisan to be presented at ASRM

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials

May 31, 2016: BioSpecifics Technologies Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology

May 18, 2016: Repros Reports Positive Clinical Data for Oral Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids

Apr 12, 2016: Repros Reports Positive Clinical Data for Vaginal Proellex in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

Jan 28, 2016: AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids

Dec 21, 2015: Repros Updates Proellex Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Dongkook Pharmaceutical Co Ltd, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Ogeda SA, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc, H1

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Company Ltd, H1

Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1

Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1

List of Figures:

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Bayer AG
  • BioSpecifics Technologies Corp
  • Dongkook Pharmaceutical Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Laboratoire HRA Pharma
  • Ogeda SA
  • Repros Therapeutics Inc
  • Takeda Pharmaceutical Company Ltd
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll